drugset / Trial / NCT01920737

A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia

NCT01920737

NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to find out whether the combination of chemotherapy drugs that are routinely used in children with ALL, will be safe and effective in treating adult patients with ALL. The standard treatment for adults with ALL consists of many chemotherapy drugs that are given in different combinations and in several steps. In adult ALL there is no standard which drugs to give and how to combine them. Some leukemias have a chromosome abnormality called Philadelphia chromosome (also called Ph Positive) and some leukemias do not (called Ph Negative). In this study we want to see whether this combination of chemotherapy drugs will be safe and effective in treating adult patients with Ph Negative ALL.

Timeline

Start
2013-08-07
Primary completion
2026-08
Completion
2026-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegaspargase Protein / enzyme biologic 2000 unknown Other
Background Cyclophosphamide Other / unclassified
Background Cytarabine Small molecule
Background Daunorubicin Small molecule
Background Dexamethasone Small molecule
Background Leucovorin Small molecule
Background MERCAPTOPURINE ANHYDROUS Small molecule
Background Methotrexate Small molecule
Background Prednisone Other / unclassified
Background Vincristine Small molecule

Indications